SAB Biotherapeutics Reports Q1 Financial Results with Significant Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Should l Buy SABS?
Source: seekingalpha
- Net Loss Overview: SAB Biotherapeutics reported a net loss of $18.9 million for Q1 2026, a significant increase from a $5.2 million loss in Q1 2025, indicating heightened financial strain on the company.
- Other Income Decline: The company recorded other income of $1.1 million in Q1 2026, down from $5.6 million in the same period last year, primarily due to changes in the fair value of warrant liabilities, highlighting challenges in its financing strategy.
- Cash Position: As of March 31, 2026, SAB Biotherapeutics held $217.6 million in cash, cash equivalents, and available-for-sale securities, providing operational runway through 2028 despite ongoing losses, which is crucial for sustaining operations.
- Market Reaction: The company's stock price fell by 5% following the earnings report, and it announced an $85 million stock offering, which may dilute existing shareholders' equity and reflects market concerns regarding the company's financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SABS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SABS
Wall Street analysts forecast SABS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.550
Low
7.00
Averages
10.33
High
15.00
Current: 3.550
Low
7.00
Averages
10.33
High
15.00
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SAB Biotherapeutics Reports Q1 Financial Results with Significant Loss
- Net Loss Overview: SAB Biotherapeutics reported a net loss of $18.9 million for Q1 2026, a significant increase from a $5.2 million loss in Q1 2025, indicating heightened financial strain on the company.
- Other Income Decline: The company recorded other income of $1.1 million in Q1 2026, down from $5.6 million in the same period last year, primarily due to changes in the fair value of warrant liabilities, highlighting challenges in its financing strategy.
- Cash Position: As of March 31, 2026, SAB Biotherapeutics held $217.6 million in cash, cash equivalents, and available-for-sale securities, providing operational runway through 2028 despite ongoing losses, which is crucial for sustaining operations.
- Market Reaction: The company's stock price fell by 5% following the earnings report, and it announced an $85 million stock offering, which may dilute existing shareholders' equity and reflects market concerns regarding the company's financial health.
See More
SAB Biotherapeutics Advances SAFEGUARD Trial Enrollment
- Trial Progress: The SAFEGUARD trial for SAB-142 is on track to enroll 159 Stage 3 diabetes patients by the end of 2026, demonstrating the company's strong execution capabilities and the urgent market need for innovative diabetes therapies.
- Strong Financial Position: SAB BIO raised $95 million through a recent public offering, resulting in a total cash position of $217.6 million, ensuring operational runway through 2028 to support the SAFEGUARD trial and pre-commercial activities.
- Positive Clinical Data: Phase 1 results for SAB-142 show C-peptide preservation and improved glycemic control, with mean time in range increasing from 73% at baseline to 85% at Day 120, laying a solid foundation for future market introduction.
- Strategic Manufacturing Agreement: SAB BIO has secured a long-term strategic manufacturing agreement with Emergent BioSolutions to support clinical and commercial production of SAB-142, further enhancing the company's competitive position in the diabetes treatment market.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, of which $36 million is contingent on future regulatory approvals and milestones, reflecting both companies' confidence in advancing drug development.
- Comprehensive Manufacturing Services: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices, including process development, technology transfer, and clinical and commercial manufacturing for SAB-142, ensuring product quality and compliance.
- Facility Advantage: Emergent's Winnipeg manufacturing facility, recognized for its expertise in plasma-derived and complex biologics, has been selected as the primary site for the development and production of SAB-142, enhancing production efficiency and accelerating clinical timelines.
- Deepening Strategic Collaboration: This partnership not only highlights Emergent's manufacturing capabilities in the biopharmaceutical sector but also underscores SAB BIO's innovative potential in treating autoimmune type 1 diabetes, which could transform the treatment landscape for this condition.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
See More
SAB Biotherapeutics Reports Q1 Financial Results with Significant Loss
- Net Loss Overview: SAB Biotherapeutics reported a net loss of $18.9 million for Q1 2026, a significant increase from a $5.2 million loss in Q1 2025, indicating heightened financial strain on the company.
- Other Income Decline: The company recorded other income of $1.1 million in Q1 2026, down from $5.6 million in the same period last year, primarily due to changes in the fair value of warrant liabilities, highlighting challenges in its financing strategy.
- Cash Position: As of March 31, 2026, SAB Biotherapeutics held $217.6 million in cash, cash equivalents, and available-for-sale securities, providing operational runway through 2028 despite ongoing losses, which is crucial for sustaining operations.
- Market Reaction: The company's stock price fell by 5% following the earnings report, and it announced an $85 million stock offering, which may dilute existing shareholders' equity and reflects market concerns regarding the company's financial health.
See More
SAB Biotherapeutics Advances SAFEGUARD Trial Enrollment
- Trial Progress: The SAFEGUARD trial for SAB-142 is on track to enroll 159 Stage 3 diabetes patients by the end of 2026, demonstrating the company's strong execution capabilities and the urgent market need for innovative diabetes therapies.
- Strong Financial Position: SAB BIO raised $95 million through a recent public offering, resulting in a total cash position of $217.6 million, ensuring operational runway through 2028 to support the SAFEGUARD trial and pre-commercial activities.
- Positive Clinical Data: Phase 1 results for SAB-142 show C-peptide preservation and improved glycemic control, with mean time in range increasing from 73% at baseline to 85% at Day 120, laying a solid foundation for future market introduction.
- Strategic Manufacturing Agreement: SAB BIO has secured a long-term strategic manufacturing agreement with Emergent BioSolutions to support clinical and commercial production of SAB-142, further enhancing the company's competitive position in the diabetes treatment market.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, of which $36 million is contingent on future regulatory approvals and milestones, reflecting both companies' confidence in advancing drug development.
- Comprehensive Manufacturing Services: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices, including process development, technology transfer, and clinical and commercial manufacturing for SAB-142, ensuring product quality and compliance.
- Facility Advantage: Emergent's Winnipeg manufacturing facility, recognized for its expertise in plasma-derived and complex biologics, has been selected as the primary site for the development and production of SAB-142, enhancing production efficiency and accelerating clinical timelines.
- Deepening Strategic Collaboration: This partnership not only highlights Emergent's manufacturing capabilities in the biopharmaceutical sector but also underscores SAB BIO's innovative potential in treating autoimmune type 1 diabetes, which could transform the treatment landscape for this condition.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
See More
